Concepts (264)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alcohol Drinking | 36 | 2022 | 273 | 9.500 |
Why?
|
| Ethanol | 30 | 2022 | 252 | 6.730 |
Why?
|
| Alcoholism | 19 | 2022 | 178 | 6.420 |
Why?
|
| Smoking Cessation | 23 | 2019 | 254 | 6.410 |
Why?
|
| Smoking | 26 | 2019 | 624 | 6.150 |
Why?
|
| Naltrexone | 16 | 2019 | 136 | 4.830 |
Why?
|
| Electronic Nicotine Delivery Systems | 8 | 2021 | 73 | 4.080 |
Why?
|
| Cues | 9 | 2021 | 174 | 3.410 |
Why?
|
| Narcotic Antagonists | 12 | 2019 | 160 | 3.250 |
Why?
|
| Reward | 6 | 2022 | 190 | 2.160 |
Why?
|
| Vaping | 4 | 2021 | 45 | 2.060 |
Why?
|
| Tobacco Use Disorder | 7 | 2019 | 115 | 1.990 |
Why?
|
| Alcoholic Beverages | 4 | 2021 | 13 | 1.920 |
Why?
|
| Hydrocortisone | 13 | 2015 | 302 | 1.770 |
Why?
|
| Adult | 77 | 2021 | 26694 | 1.730 |
Why?
|
| Young Adult | 43 | 2021 | 6347 | 1.710 |
Why?
|
| Central Nervous System Depressants | 9 | 2021 | 45 | 1.700 |
Why?
|
| Craving | 5 | 2019 | 22 | 1.630 |
Why?
|
| Double-Blind Method | 25 | 2019 | 1722 | 1.530 |
Why?
|
| Tobacco Products | 4 | 2021 | 64 | 1.470 |
Why?
|
| Male | 77 | 2021 | 42558 | 1.420 |
Why?
|
| Alcoholic Intoxication | 4 | 2015 | 32 | 1.390 |
Why?
|
| Psychomotor Performance | 8 | 2018 | 496 | 1.310 |
Why?
|
| Mobile Applications | 2 | 2021 | 71 | 1.310 |
Why?
|
| Female | 75 | 2021 | 46354 | 1.300 |
Why?
|
| Alcohol-Related Disorders | 3 | 2021 | 18 | 1.290 |
Why?
|
| Tobacco Use Cessation | 2 | 2017 | 7 | 1.150 |
Why?
|
| Tobacco Smoke Pollution | 2 | 2018 | 25 | 1.060 |
Why?
|
| Humans | 89 | 2022 | 89621 | 1.050 |
Why?
|
| Behavior, Addictive | 5 | 2019 | 134 | 1.050 |
Why?
|
| Hypnotics and Sedatives | 3 | 2017 | 131 | 0.980 |
Why?
|
| Sexual and Gender Minorities | 2 | 2019 | 211 | 0.960 |
Why?
|
| Smokers | 3 | 2021 | 46 | 0.960 |
Why?
|
| Surveys and Questionnaires | 13 | 2019 | 2641 | 0.950 |
Why?
|
| Motivation | 5 | 2021 | 296 | 0.930 |
Why?
|
| Psychometrics | 6 | 2018 | 330 | 0.860 |
Why?
|
| Self Efficacy | 2 | 2019 | 56 | 0.750 |
Why?
|
| Impulsive Behavior | 3 | 2019 | 287 | 0.750 |
Why?
|
| Longitudinal Studies | 4 | 2021 | 1076 | 0.740 |
Why?
|
| Dose-Response Relationship, Drug | 10 | 2020 | 1944 | 0.730 |
Why?
|
| Patient Selection | 2 | 2017 | 684 | 0.710 |
Why?
|
| Sex Factors | 9 | 2018 | 1068 | 0.690 |
Why?
|
| Psychiatric Status Rating Scales | 4 | 2018 | 492 | 0.690 |
Why?
|
| Follow-Up Studies | 8 | 2017 | 3671 | 0.690 |
Why?
|
| Self Report | 5 | 2020 | 297 | 0.690 |
Why?
|
| Saccades | 3 | 2013 | 69 | 0.690 |
Why?
|
| Smartphone | 1 | 2019 | 39 | 0.670 |
Why?
|
| Genotype | 3 | 2019 | 1852 | 0.660 |
Why?
|
| Receptors, Opioid | 1 | 2019 | 23 | 0.650 |
Why?
|
| Nicotine | 4 | 2013 | 199 | 0.640 |
Why?
|
| Glycerol | 1 | 2019 | 35 | 0.640 |
Why?
|
| Vegetables | 1 | 2019 | 47 | 0.640 |
Why?
|
| Tobacco Smoking | 1 | 2019 | 29 | 0.640 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 1 | 2018 | 36 | 0.630 |
Why?
|
| Central Nervous System Stimulants | 2 | 2019 | 219 | 0.620 |
Why?
|
| Research Design | 2 | 2012 | 601 | 0.620 |
Why?
|
| Treatment Outcome | 13 | 2019 | 8273 | 0.620 |
Why?
|
| Tobacco Use | 1 | 2018 | 27 | 0.600 |
Why?
|
| Stimulation, Chemical | 1 | 2017 | 63 | 0.580 |
Why?
|
| Social Behavior | 4 | 2018 | 299 | 0.580 |
Why?
|
| Substance Withdrawal Syndrome | 4 | 2012 | 47 | 0.580 |
Why?
|
| Pituitary-Adrenal System | 3 | 2012 | 64 | 0.560 |
Why?
|
| Professional Practice | 1 | 2017 | 46 | 0.560 |
Why?
|
| Homosexuality, Female | 1 | 2017 | 15 | 0.560 |
Why?
|
| Binge Drinking | 2 | 2013 | 13 | 0.560 |
Why?
|
| Hypothalamo-Hypophyseal System | 3 | 2012 | 81 | 0.560 |
Why?
|
| Bisexuality | 1 | 2017 | 33 | 0.560 |
Why?
|
| Affect | 8 | 2012 | 387 | 0.550 |
Why?
|
| Health Personnel | 1 | 2019 | 215 | 0.550 |
Why?
|
| Sex Characteristics | 4 | 2012 | 327 | 0.550 |
Why?
|
| Research Subjects | 1 | 2017 | 74 | 0.540 |
Why?
|
| Transsexualism | 1 | 2017 | 33 | 0.540 |
Why?
|
| Health Promotion | 3 | 2014 | 165 | 0.530 |
Why?
|
| Referral and Consultation | 1 | 2019 | 342 | 0.520 |
Why?
|
| Psychotherapy, Brief | 1 | 2015 | 12 | 0.510 |
Why?
|
| Middle Aged | 29 | 2019 | 26069 | 0.510 |
Why?
|
| Feedback, Psychological | 1 | 2015 | 19 | 0.510 |
Why?
|
| Weight Gain | 2 | 2012 | 119 | 0.500 |
Why?
|
| Luteal Phase | 1 | 2014 | 14 | 0.490 |
Why?
|
| Follicular Phase | 1 | 2014 | 11 | 0.490 |
Why?
|
| Drinking Behavior | 1 | 2014 | 13 | 0.490 |
Why?
|
| Prolactin | 1 | 2014 | 89 | 0.480 |
Why?
|
| Polymorphism, Genetic | 1 | 2018 | 826 | 0.480 |
Why?
|
| Saliva | 7 | 2015 | 124 | 0.470 |
Why?
|
| Stress, Psychological | 5 | 2013 | 321 | 0.450 |
Why?
|
| Psychotherapy, Group | 2 | 2013 | 34 | 0.450 |
Why?
|
| Smoking Prevention | 3 | 2014 | 45 | 0.440 |
Why?
|
| Community Health Services | 1 | 2014 | 82 | 0.440 |
Why?
|
| Homosexuality, Male | 1 | 2017 | 302 | 0.440 |
Why?
|
| Eye Movements | 2 | 2012 | 119 | 0.440 |
Why?
|
| Disruptive, Impulse Control, and Conduct Disorders | 3 | 2016 | 282 | 0.430 |
Why?
|
| Breath Tests | 4 | 2022 | 57 | 0.420 |
Why?
|
| HIV Seropositivity | 1 | 2013 | 51 | 0.420 |
Why?
|
| Nicotinic Agonists | 2 | 2012 | 73 | 0.420 |
Why?
|
| Biomedical Research | 1 | 2017 | 400 | 0.410 |
Why?
|
| Pilot Projects | 6 | 2019 | 873 | 0.410 |
Why?
|
| Sexual Partners | 1 | 2013 | 101 | 0.400 |
Why?
|
| Medical Records | 1 | 2012 | 120 | 0.400 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 605 | 0.390 |
Why?
|
| Internet | 2 | 2019 | 320 | 0.380 |
Why?
|
| Feasibility Studies | 4 | 2020 | 783 | 0.380 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2015 | 841 | 0.370 |
Why?
|
| Mental Recall | 1 | 2012 | 162 | 0.370 |
Why?
|
| Eligibility Determination | 1 | 2011 | 36 | 0.370 |
Why?
|
| Sexual Behavior | 1 | 2013 | 311 | 0.350 |
Why?
|
| Pursuit, Smooth | 2 | 2013 | 32 | 0.340 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2014 | 539 | 0.340 |
Why?
|
| Basal Ganglia | 1 | 2009 | 46 | 0.340 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2013 | 261 | 0.340 |
Why?
|
| Physicians | 1 | 2017 | 690 | 0.330 |
Why?
|
| Adolescent | 11 | 2021 | 9288 | 0.330 |
Why?
|
| Brief Psychiatric Rating Scale | 1 | 2009 | 6 | 0.330 |
Why?
|
| Chicago | 5 | 2019 | 1428 | 0.320 |
Why?
|
| Amygdala | 3 | 2016 | 86 | 0.320 |
Why?
|
| Social Environment | 2 | 2007 | 187 | 0.320 |
Why?
|
| Substance-Related Disorders | 4 | 2020 | 416 | 0.320 |
Why?
|
| Analysis of Variance | 7 | 2016 | 900 | 0.300 |
Why?
|
| Preventive Health Services | 1 | 2008 | 39 | 0.300 |
Why?
|
| Anger | 3 | 2016 | 80 | 0.280 |
Why?
|
| Oxytocin | 2 | 2018 | 73 | 0.280 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2013 | 1366 | 0.270 |
Why?
|
| Attitude to Health | 1 | 2008 | 223 | 0.270 |
Why?
|
| Time Factors | 5 | 2014 | 5344 | 0.270 |
Why?
|
| Residence Characteristics | 1 | 2008 | 202 | 0.260 |
Why?
|
| Cultural Characteristics | 2 | 2019 | 18 | 0.260 |
Why?
|
| Head and Neck Neoplasms | 1 | 2013 | 1063 | 0.260 |
Why?
|
| Family Health | 2 | 2018 | 162 | 0.250 |
Why?
|
| Substance Abuse Treatment Centers | 2 | 2004 | 24 | 0.240 |
Why?
|
| Cohort Studies | 3 | 2019 | 2878 | 0.240 |
Why?
|
| Patient Dropouts | 1 | 2004 | 30 | 0.230 |
Why?
|
| Photic Stimulation | 4 | 2015 | 502 | 0.220 |
Why?
|
| Prospective Studies | 3 | 2019 | 4310 | 0.220 |
Why?
|
| Aged | 10 | 2014 | 19237 | 0.210 |
Why?
|
| Prevalence | 4 | 2020 | 1246 | 0.210 |
Why?
|
| Life Change Events | 1 | 2003 | 48 | 0.210 |
Why?
|
| Counseling | 3 | 2015 | 164 | 0.210 |
Why?
|
| Health Behavior | 2 | 2017 | 186 | 0.190 |
Why?
|
| Personality | 1 | 2003 | 134 | 0.190 |
Why?
|
| Risk Reduction Behavior | 2 | 2013 | 97 | 0.190 |
Why?
|
| Program Evaluation | 3 | 2013 | 308 | 0.180 |
Why?
|
| Marijuana Smoking | 1 | 2020 | 28 | 0.170 |
Why?
|
| Marketing | 1 | 2019 | 23 | 0.170 |
Why?
|
| Women | 1 | 2019 | 25 | 0.170 |
Why?
|
| Environment | 1 | 2021 | 223 | 0.170 |
Why?
|
| Exhalation | 1 | 2019 | 7 | 0.170 |
Why?
|
| Aerosols | 1 | 2019 | 45 | 0.160 |
Why?
|
| Behavior Therapy | 1 | 2019 | 87 | 0.160 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2019 | 2408 | 0.160 |
Why?
|
| Heart Rate | 2 | 2018 | 498 | 0.160 |
Why?
|
| Phenotype | 2 | 2015 | 2447 | 0.150 |
Why?
|
| Heterozygote | 1 | 2018 | 373 | 0.150 |
Why?
|
| China | 2 | 2015 | 234 | 0.140 |
Why?
|
| Adrenocorticotropic Hormone | 3 | 2009 | 131 | 0.140 |
Why?
|
| Illinois | 1 | 2019 | 483 | 0.140 |
Why?
|
| Culture | 1 | 2017 | 53 | 0.140 |
Why?
|
| Administration, Oral | 2 | 2012 | 682 | 0.140 |
Why?
|
| Reproducibility of Results | 2 | 2021 | 2763 | 0.140 |
Why?
|
| Disease Progression | 1 | 2021 | 1492 | 0.130 |
Why?
|
| Risk Factors | 4 | 2013 | 5516 | 0.130 |
Why?
|
| Depression | 1 | 2020 | 509 | 0.130 |
Why?
|
| Retinal Rod Photoreceptor Cells | 1 | 2015 | 9 | 0.130 |
Why?
|
| Patient-Centered Care | 2 | 2020 | 209 | 0.130 |
Why?
|
| Retinal Cone Photoreceptor Cells | 1 | 2015 | 43 | 0.120 |
Why?
|
| Qualitative Research | 1 | 2017 | 302 | 0.120 |
Why?
|
| Alcohol Abstinence | 1 | 2014 | 7 | 0.120 |
Why?
|
| Mental Disorders | 1 | 2019 | 416 | 0.120 |
Why?
|
| Severity of Illness Index | 3 | 2015 | 1847 | 0.120 |
Why?
|
| Socioeconomic Factors | 2 | 2014 | 591 | 0.120 |
Why?
|
| Interviews as Topic | 2 | 2013 | 344 | 0.120 |
Why?
|
| Retrospective Studies | 3 | 2019 | 9089 | 0.110 |
Why?
|
| United States | 3 | 2020 | 7020 | 0.110 |
Why?
|
| Cotinine | 1 | 2013 | 12 | 0.110 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2013 | 18 | 0.110 |
Why?
|
| Mass Screening | 2 | 2008 | 637 | 0.110 |
Why?
|
| Administration, Cutaneous | 1 | 2013 | 60 | 0.110 |
Why?
|
| Health Services Accessibility | 1 | 2017 | 431 | 0.110 |
Why?
|
| Color Vision Defects | 1 | 2012 | 22 | 0.110 |
Why?
|
| Cross-Over Studies | 2 | 2013 | 389 | 0.100 |
Why?
|
| Aggression | 1 | 2016 | 322 | 0.100 |
Why?
|
| Genetics, Behavioral | 1 | 2012 | 22 | 0.100 |
Why?
|
| Papillomaviridae | 1 | 2013 | 156 | 0.100 |
Why?
|
| Contrast Sensitivity | 1 | 2012 | 70 | 0.100 |
Why?
|
| Quinoxalines | 1 | 2012 | 50 | 0.100 |
Why?
|
| Amphetamine | 1 | 2012 | 103 | 0.100 |
Why?
|
| Visual Pathways | 1 | 2012 | 153 | 0.100 |
Why?
|
| Benzazepines | 1 | 2012 | 64 | 0.100 |
Why?
|
| Prefrontal Cortex | 1 | 2013 | 136 | 0.100 |
Why?
|
| Emotions | 2 | 2016 | 351 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2016 | 3461 | 0.100 |
Why?
|
| Community Health Centers | 1 | 2013 | 117 | 0.100 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2018 | 2353 | 0.090 |
Why?
|
| Fear | 1 | 2010 | 79 | 0.090 |
Why?
|
| Patient Compliance | 2 | 2009 | 231 | 0.090 |
Why?
|
| Papillomavirus Infections | 1 | 2013 | 262 | 0.090 |
Why?
|
| Age Factors | 1 | 2014 | 1874 | 0.080 |
Why?
|
| Biomarkers | 2 | 2013 | 1770 | 0.080 |
Why?
|
| Placebos | 1 | 2009 | 214 | 0.080 |
Why?
|
| Program Development | 1 | 2009 | 123 | 0.080 |
Why?
|
| Alanine Transaminase | 1 | 2009 | 72 | 0.080 |
Why?
|
| Aspartate Aminotransferases | 1 | 2009 | 75 | 0.080 |
Why?
|
| Body Weight | 1 | 2010 | 452 | 0.080 |
Why?
|
| Patients | 1 | 2010 | 102 | 0.080 |
Why?
|
| Dextroamphetamine | 1 | 2010 | 108 | 0.080 |
Why?
|
| Combined Modality Therapy | 1 | 2012 | 1720 | 0.080 |
Why?
|
| Pain Measurement | 1 | 2009 | 331 | 0.080 |
Why?
|
| Pharmacogenetics | 1 | 2012 | 443 | 0.080 |
Why?
|
| Arousal | 2 | 2005 | 170 | 0.070 |
Why?
|
| Psychological Tests | 1 | 2008 | 91 | 0.070 |
Why?
|
| Wechsler Scales | 1 | 2007 | 21 | 0.070 |
Why?
|
| Health Status Indicators | 1 | 2008 | 103 | 0.070 |
Why?
|
| Administration, Intranasal | 2 | 2018 | 139 | 0.070 |
Why?
|
| Psychopharmacology | 1 | 2006 | 26 | 0.070 |
Why?
|
| Temperance | 2 | 2003 | 6 | 0.070 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2007 | 219 | 0.070 |
Why?
|
| Chi-Square Distribution | 2 | 2004 | 360 | 0.070 |
Why?
|
| Behavior | 1 | 2006 | 85 | 0.070 |
Why?
|
| Models, Psychological | 1 | 2006 | 158 | 0.060 |
Why?
|
| Neoplasms | 1 | 2020 | 3079 | 0.060 |
Why?
|
| Liver | 1 | 2009 | 1210 | 0.060 |
Why?
|
| Anxiety | 2 | 2020 | 311 | 0.060 |
Why?
|
| Aged, 80 and over | 1 | 2014 | 6834 | 0.060 |
Why?
|
| Forecasting | 1 | 2004 | 306 | 0.050 |
Why?
|
| Personality Assessment | 1 | 2003 | 97 | 0.050 |
Why?
|
| Choice Behavior | 1 | 2004 | 160 | 0.050 |
Why?
|
| Biotransformation | 1 | 2002 | 50 | 0.050 |
Why?
|
| Stress, Physiological | 1 | 2003 | 232 | 0.050 |
Why?
|
| Multivariate Analysis | 1 | 2004 | 988 | 0.050 |
Why?
|
| Blood Alcohol Content | 1 | 2021 | 6 | 0.050 |
Why?
|
| Alcohol Deterrents | 1 | 2020 | 2 | 0.040 |
Why?
|
| Cognition Disorders | 1 | 2002 | 234 | 0.040 |
Why?
|
| Crohn Disease | 1 | 2007 | 762 | 0.040 |
Why?
|
| Logistic Models | 1 | 2004 | 1214 | 0.040 |
Why?
|
| Colitis, Ulcerative | 1 | 2007 | 740 | 0.040 |
Why?
|
| Adaptation, Psychological | 1 | 2020 | 166 | 0.040 |
Why?
|
| Terminology as Topic | 1 | 2020 | 221 | 0.040 |
Why?
|
| Oxytocics | 1 | 2018 | 24 | 0.040 |
Why?
|
| Universities | 1 | 2019 | 148 | 0.040 |
Why?
|
| Hypertension | 1 | 2003 | 747 | 0.040 |
Why?
|
| Reference Values | 2 | 2012 | 661 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 1152 | 0.030 |
Why?
|
| Healthy Volunteers | 1 | 2013 | 146 | 0.030 |
Why?
|
| Psychophysics | 1 | 2012 | 80 | 0.030 |
Why?
|
| Comorbidity | 1 | 2016 | 951 | 0.030 |
Why?
|
| Varenicline | 1 | 2012 | 14 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2015 | 901 | 0.020 |
Why?
|
| Neural Pathways | 1 | 2013 | 319 | 0.020 |
Why?
|
| Nausea | 1 | 2012 | 176 | 0.020 |
Why?
|
| Body Image | 1 | 2010 | 78 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2016 | 1253 | 0.020 |
Why?
|
| Income | 1 | 2009 | 85 | 0.020 |
Why?
|
| Individuality | 1 | 2010 | 110 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2012 | 858 | 0.020 |
Why?
|
| Quality Assurance, Health Care | 1 | 2010 | 225 | 0.020 |
Why?
|
| Age of Onset | 1 | 2007 | 313 | 0.020 |
Why?
|
| Hemodynamics | 1 | 2010 | 731 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2010 | 1728 | 0.020 |
Why?
|
| Remission, Spontaneous | 1 | 2003 | 53 | 0.010 |
Why?
|
| Isometric Contraction | 1 | 2003 | 42 | 0.010 |
Why?
|
| Hand Strength | 1 | 2003 | 52 | 0.010 |
Why?
|
| Patient Admission | 1 | 2003 | 114 | 0.010 |
Why?
|
| Speech | 1 | 2003 | 85 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2009 | 1048 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2002 | 590 | 0.010 |
Why?
|
| Neuropsychological Tests | 1 | 2002 | 506 | 0.010 |
Why?
|